Lung cancer is the number one cancer killer worldwide afflicting the lives of 1.8 million annually.\[[@ref1]\] In Saudi Arabia, lung cancer is on the rise increasingly claiming lives as the major risk factor causing it, namely smoking in various forms, and is on the rise in all age groups and genders.\[[@ref2]\] In 2014, lung cancer ranked fourth among Saudi males and seventeenth among Saudi females. There were 452 documented cases of lung cancer accounted for 3.9% of all newly diagnosed cases among Saudis in 2014. Lung cancer affected 354 (78.3%) males and 98 (21.7%) females, with a male-to-female ratio of 361:100. The Age standardized rate (ASR was 5.3/100,000 for males and 1.4/100,000 for females.\[[@ref2]\] In Canada, lung cancer is the most commonly diagnosed form of cancer (26,600 new cases in 2015; 51.9 per 100,000) as well as the main cause of cancer-related mortality among Canadians (21,100 estimated deaths in 2017; 51.4 per year 100,000).\[[@ref3]\] In the United States, the incidence of lung cancer (estimated 234,030; 54.6 per 100,000, data for 2011--2015) is second only to the incidence of breast cancer but tops all other forms as the leading cause of cancer deaths (estimated 154,050; 43.4 per 100,000, data for 2011--2015). In both countries, almost all (\>90%) new cases of lung cancer in 2016--2017 are expected to be identified in adults aged 50 years and older.\[[@ref3][@ref4]\]

Smoking causes cancer not only among smokers themselves but also among exposed individuals at workplace or home. Other industrial/environmental risk factors such as asbestos exposure and others account for smaller fraction of cancer cases.

When diagnosed, lung cancer kills 85% of its victims. However, what is promising in the fight against lung cancer is the fact that it is largely preventable.\[[@ref5]\] Avoiding tobacco will eliminate 85% of lung cancer cases.

Therefore, the primary prevention of lung cancer by avoiding tobacco is a very effective strategy. On the other hand, cure rate for cases diagnosed early in Stage I can be up to 85% which steeps down to 1% in Stage IV.

In conclusion, detection of lung cancer at earlier stage does improve the overall survival of patients. Finally, major efforts should be directed toward preventing lung cancer from occurring in the first place by tobacco control and in high risk patients, detect cancer in early, highly curable stage..

Methods {#sec1-1}
=======

A multidisciplinary team including consultants from different disciplines was invited by National Cancer Center at Saudi Health Council to form the Lung Cancer Prevention and Screening Committee. The Committee included consultants in thoracic surgery, pulmonary medicine, medical imaging, oncology, and primary care representing different healthcare sectors in the Kingdom of Saudi Arabia. The committee worked in collaboration with Saudi Lung Cancer Association (SLCA) of the Saudi Thoracic Society.

The team set the objective of the guidelines and decided to follow the previously established format and same categories of level of evidence by the SLCA when published in the Saudi Lung Cancer Guidelines 2017.\[[@ref6]\]

The guidelines level is as follows:

(EL-1) High level: Well-conducted phase III randomized studies or meta-analysis(EL-2) Intermediate level: Good phase II data or phase III trials with limitations(EL-3) Low level: Observational/retrospective study/expert opinion.

The guidelines are divided into primary prevention, early detection, and screening. Various guidelines were reviewed from the literature of local data and then constructed the guidelines. The guidelines were reviewed internally by all members and externally by the Director of National Cancer Center.

Lung cancer primary prevention {#sec2-1}
------------------------------

The prevention of lung cancer is centered around tobacco control. This daunting task is the responsibility of multiple entities from national governing bodies all the way down to the individual level as shown in [Table 1](#T1){ref-type="table"}. These guidelines focus on the healthcare professionals\' role in prevention.

###### 

Roles of various entities in tobacco control
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In this monograph, our multidisciplinary multicenter national group provides guidelines for primary lung cancer prevention and lung cancer screening.

Management Guidelines for Tobacco Control for Healthcare Providers {#sec1-2}
==================================================================

Overview {#sec2-2}
--------

Stop smoking cessation interventions and services should be available in primary care and community settings for everyone over the age of 12 years.\[[@ref7]\] The aim of these guidelines is to ensure that everyone who smokes is screened for smoking and is given the required advice and motivation to stop and all the assistance they might need for quitting and preventing relapse.\[[@ref8]\]

General measures {#sec2-3}
----------------

Use local statistics to estimate smoking prevalence among the local population\[[@ref9]\]Prioritize specific groups who are at high risk of tobacco-related harmAssure that your facility is smoke-free facility and your patient and staff are not smoking in areas that are not designated for smokingIf you are a smoker, stop smoking, seek help if needed. It is advisable for your own, your family\'s, and your patients\' health. You will be a good role model to your patients. It was found that smoking physicians are less likely to counsel their patients about smoking\[[@ref10]\]Acquire and provide smoking cessations tools and materials in your facilityAttend smoking cessations training workshop, if possibleIdentify local/community resources to refer your patients, when needed.

Screening patients for smoking {#sec2-4}
------------------------------

Ask all your patients systematically if they smoke or not. Make it part of their vital signs\[[@ref11]\] (EL-1)Monitor stop smoking services by setting targets, including the number of people using the service and the proportion who successfully quit smoking\[[@ref7]\]If a smoker is identified, implement smoking cessation guidelines of point 3.

Smoking cessation intervention {#sec2-5}
------------------------------

If a patient is identified as a current smoker, counseling should be provided.

Provide smoking cessation counseling using the 5A technique (Ask, Advise, Assess, Assist, and Arrange) or any other proven approach (EL-1)\[[@ref8]\] \[[Table 2](#T2){ref-type="table"}\]Once a tobacco user is identified and advised to quit, a clinician should assess the patient\'s willingness to quit at this timeTobacco dependence treatment (such as medication) is effective and should be delivered to every individual even if the specialized assessment is not used or available (EL-1)If the patient is not ready to quit, use motivational intervention. To motivate the patient, consider quit attempt with the "5 R\'s" (Relevance, Risk, Reward, Roadblocks, and Repetition) (EL-2)\[[@ref8][@ref12]\] \[[Table 3](#T3){ref-type="table"}\]Cognitive behavioral therapy and support (counseling) involves delivering evidence-based behavior change techniques, most commonly provided face-to-face individual or groups (EL-1)Self-management technique should be used (such as print and web-based materials)\[[@ref13]\] (EL-2)Enlist the help of available resources in your communityFor all adults, use varenicline, bupropion or nicotine replacement therapy (NRT). Except where contraindicated or for specific populations for which there is insufficient evidence of effectiveness (i.e., pregnant women, smokeless tobacco users, light smokers, and adolescent) (EL-1)Agree a quit date set within the first 2 weeks of bupropion treatment and within 1--2 weeks of varenicline treatment (EL-1)Agree a quit date if NRT is prescribed. Ensure that the person has NRT ready to start the day before the quit date (EL-1)Ensure follow-up and behavioral support is providedEnsure at least a very brief advice is deliveredMonitor compliance by auditing patients\' self-reported abstinence records, using objective measures such as carbon monoxide monitoring. Success is defined as less than 10 parts per million (ppm) at 4 weeks after the quit date. This should not imply that treatment should stop at 4 weeks\[[@ref7]\]In relapsed patients, assessment has to be done to determine if they are willing to quit again (EL-3)If the patient is willing to make another quit attempt, offer behavioral support, medication, and arrange for follow-up.

###### 

The ''5 A's" model for treating tobacco use and dependence
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###### 

Enhancing motivation to quit tobacco, the "5 R's"
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Lung cancer early detection {#sec2-6}
---------------------------

Early detection of lung cancer means to discover cancer as early as possible by recognition of the possible early signs and symptoms of cancer and doing the proper workup or referral to confirm or rule out cancer. Early detection may occur proactively by screening asymptomatic patients for cancer. This section will focus on patients who present with symptom, signs, or findings suggestive of lung cancer, which should trigger "early diagnosis" of the disease.

### All patients {#sec3-1}

If a patient is asymptomatic and older than 55 with 30 pack-year (PY) history of smoking, follow Guidelines on Section IIIKeep in mind that nonsmokers and females can get lung cancer too.

### Findings that are suspicious suggestive of lung cancer {#sec3-2}

Symptoms: new onset ofNew cough lasting more than 3--4 weeks or a change in the "smoker\'s chronic cough"Hemoptysis: especially not accompanying upper respiratory infection or bronchitis, symptoms \>4 weeksChest painShortness of breathPoor appetite/weight lossSigns of physical examination findings include:CachexiaRespiratory distressClubbingFacial and neck edema and neck venous distensionSigns of pleural effusionSigns of mediastinal shiftSupraclavicular or cervical adenopathyImaging findings in asymptomatic and symptomatic patients (incidental findings):Mass with or without cavitationPleural effusionAtelectasis/volume lossMediastinal deviation or wideningLytic bone lesionsNormal X-ray• Keep in mind that chest X-ray can be normal in patients with lung cancer. Therefore, if a patient had symptoms such as hemoptysis \>4 weeks and chest X-ray is normal, obtain computed tomographic (CT) of the chest and even if the CT is normal, patient may need bronchoscopy to diagnose an endobronchial small lesion.Recurrent pneumonia in the same lobeLaboratory findings include:HypercalcemiaHyponatremia.

### Workup {#sec3-3}

Obtain good-quality chest X-ray to rule out other causes of symptoms such as pneumonia or Tuberculosis.Obtain CT scan of the chest for the following indicationsAbnormal chest X-ray, suspicious of cancerPersistent infiltrate despite antibiotic treatment for a pneumoniaNormal chest X-ray with concerning complaints such as persistent hemoptysis or cough \>4 weeksThoracentesis: For a pleural effusion in the setting of suspected malignancyBronchoscopyIf normal CT scan with suspicion of endobronchial lesionsIf there is accessible lesionInclude endobronchial ultrasound staging for hilar and mediastinal nodes if possible in the absence of distant metastasisCT-guided biopsy: For peripheral nodules or masses not accessible by bronchoscopy.

Lung cancer screening {#sec2-7}
---------------------

Lung cancer screening is proven to save lives and became the standard of care in the United States especially after National Lung Cancer Screening Trial. However, screening studies were done among a Western population where lung cancer is very prevalent and kills more people than breast, prostate, and colon cancer combined. However, given the lower prevalence in our population, such screening cannot be automatically presumed to be successful or cost-effective to be adopted. However, since we are practicing most of our medicine, based on published evidence, we propose here stringent guidelines to provide to our healthcare professionals who might like to take care of their patients based on available evidence in the literature and consider providing them with lung cancer screening.

It is very prudent that healthcare professional be aware of all the requirements \[[Table 4](#T4){ref-type="table"}\] and challenges of doing screening program before launching screening to all his/her patients.

###### 

Requirements for local lung cancer screening program or individual requests
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### Requirements for lung cancer screening program {#sec3-4}

These requirements should be considered before starting screening patients \[[Table 4](#T4){ref-type="table"}\].

Who should be screened (Section 2)Where will CT scan of chest done, would a radiologist be willing to do it, who will pay for it, will the report be standardized, who responded to do follow-up plan based on the report?What would ordering physician do if there were abnormal CT scan findings? Do they have multidisciplinary team with expertise to manage suspicious findings or have access to tertiary center that one can refer the patient to them for further workup? Confirm with the center if they accept all your referrals and how many and who is eligible for referral and the referral process? \[[Figure 1](#F1){ref-type="fig"} as prototype\]Who would call the patient and report the result and follow-up on the patient workup?Who would counsel the patient for medical and psychological issues?Must have access to/or offer smoking cessation counseling to smokers?If diagnosed with cancer, where will the patient be treated?If there was incidental finding such as coronary artery disease or emphysema, where would physician refer patient?

![Process map of Saudi lung cancer screening program](ATM-13-198-g005){#F1}

### Whom to screen {#sec3-5}

The following are candidates for lung cancer screening:

Asymptomatic patients (symptomatic patients should be worked up properly according to standards of care)Age 55--77 years\[[@ref14]\]Smoking history \>30 PY (number of packs smoked per day X year of smoking)Active smoker or quit smoking less than 15 years ago.Did not have chest CT scan the last yearDo not perform screening for individuals with comorbidities that could adversely influence their ability to tolerate the evaluation of screen-detected findings or tolerate treatment of early-stage screen-detected lung cancer or that substantially limit their life expectancy. We recommend that low-dose CT (LDCT) screening should not be performed in these situations (strong recommendation, low-quality evidence) (e.g., advanced liver disease, COPD with hypoventilation and hypoxia, NYHA class IV heart failure).\[[@ref14]\]

### What to do? {#sec3-6}

Explain to patient the screening process and potential risks and benefits and follow-up plans in case the patient opts for screening.Obtain LDCT scan of the chest\[[@ref15]\]CT examinations should be acquired using multidetector scanners with at least 16 detector rows, in a helical techniqueIntravenous contrast material should not be usedField of view: From the lung apices to the costophrenic anglesSection thickness should be 2.5 mm or less, with less than 1 mm preferredGantry rotation should be 500 msec per rotation or fasterDose: Maximum dose threshold as a volumetric CT dose index of 3 mGy for a standard-sized patient (height \[170 cm\]; weight 70 kg) with "appropriate dose reduction" for smaller patients and an appropriate increase for larger patientsOptimum low-dose protocol are established separately depending on vendor specific parameters and adjustments to match dose threshold of CT dose index of 3 mGyLung-RAD lung imaging reporting and data system is to be used in reporting as established by the American College of Radiology\[[@ref15]\]Based on the report, decide next step (Section 4 and 5)A positive test is defined as a test that leads to a recommendation for any additional testing other than to return for the annual screening examination.\[[@ref14]\]

### Managing findings on the screening computed tomographic scan (for primary care/nonspecialist) {#sec3-7}

Normal CT scan: after 1 year and then annually repeat CT scan\[[@ref12][@ref14][@ref16]\]If CT scan is positive per 3.4, compare with previous imaging, if available\[[@ref12][@ref14][@ref16]\]New lung lesions \<5 mm repeat in 12 months (later should depend on the 12 months CT)\[[@ref12][@ref14][@ref16]\]New lesions 6--7 mm repeat CT scan in 6 months\[[@ref12][@ref14][@ref16]\]New lesions \>8 mm refer to pulmonary/thoracic surgeon for workup\[[@ref12][@ref14][@ref16]\]Other findings\[[@ref12][@ref14][@ref16]\]Coronary artery disease -- refer to cardiologyChronic obstructive pulmonary disease -- assess need to refer to pulmonaryOther finding -- act based on findings

### Workup of lung cancer nodules (to be done by consultant with access to multidisciplinary team) {#sec3-8}

A multidisciplinary team including at least one consultant from each of the following specialties: radiology/interventional radiology, pulmonary/interventional, pulmonary, and thoracic surgeon. Team should review all the cases and take consensus approach to decision making.New solid lesion \>8 mm obtain CT scan with IV contrast or positron emission tomography (PET)/CT scanPET positive or suspicious CT scan obtains CT-guided or surgical excisional biopsy (resection)PET negative or low suspicion, repeat LDCT in 3 months, if still stable, repeat LDCT in 6 months, if still stable, do LDCT scan annually. If it grew, do biopsy or surgical resectionManagement of part-solid lung nodules\<5 mm: annual LDCT\>6 mm with \<5 mm solid component: LDCT in 6 months\>6 mm with 6--7 mm solid component: LDCT in 3 months or PET scan\>8 mm solid component: CT chest with IV contrast, if highly suspicious: biopsy or surgical excision\[[@ref17]\]New nonsolid lesion:\<19 mm repeat LDCT in 6 months, if stable annual LDCT, if grew, biopsy or surgical resection\>20 mm repeat LDCT in 3 months, if stable repeat in 6 months, then annual. If grew, do biopsy or surgical resectionManagement of multiple lung nodules:Purely solid: Measure and manage the largest and as solid nodulesNodules with partly solid component: Measure and manage the largest as part-solid nodule.
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